Tirzepatide

Tirzepatide (CAS 2023788-19-2; MW ~4813.5 g/mol) is a 39-amino acid dual GLP-1R/GIPR agonist developed by Eli Lilly — the foundational molecule establishing dual incretin co-agonism as the dominant weight loss paradigm. FDA-approved for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023). Mechanism: GLP-1R activation handles appetite suppression and insulin secretion; GIPR activation provides complementary effects on adipocyte differentiation, lipid metabolism, and enhanced insulin dynamics — producing superior weight loss vs. GLP-1 single agonist. SURMOUNT-1 trials: 15 mg/week achieved a mean body weight reduction of 22.5% at 72 weeks in participants without diabetes — substantially superior to semaglutide. SURMOUNT-5 head-to-head vs. semaglutide: tirzepatide showed significantly greater weight loss. The GIPR co-agonism component is also being studied for NASH, heart failure, sleep apnea, and knee osteoarthritis. A C20 fatty diacid provides once-weekly albumin-binding extended half-life.

This dual incretin analog represents a paradigm shift in metabolic research, demonstrating that co-activation of GLP-1 and GIP receptors produces synergistic effects exceeding either receptor alone. The GIP receptor component, previously thought to be counterproductive for weight loss, actually enhances the metabolic benefits when combined with GLP-1 activation, improving insulin sensitivity, lipid handling, and adipocyte function.

In research applications, tirzepatide demonstrates superior efficacy across multiple metabolic endpoints compared to GLP-1 mono-agonists. The dual mechanism addresses appetite regulation through both GLP-1 and GIP pathways in the central nervous system, while peripheral actions enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and improve adipocyte lipid metabolism. The GIP component also demonstrates anti-inflammatory effects and may protect against beta-cell exhaustion.

The SURMOUNT clinical program provides extensive human data supporting tirzepatide's efficacy and safety profile, with dose-dependent weight loss reaching 22.5% at the highest dose. Ongoing studies are investigating applications in NASH, cardiovascular disease, obstructive sleep apnea, and osteoarthritis, expanding the therapeutic potential of dual incretin agonism beyond glycemic control and weight management.